ACCORD HEALTHCARE, INC. recalls Levothyroxine Sodium Tablets
- Published
- 15 Oct 2025
- Units affected
- 54,432 bottles
- Agency
- FDA
- Country
- United States
The hazard
Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-450-15.
- Brand / company
- ACCORD HEALTHCARE, INC.
- Codes / lots
- Lot # D2300045, Exp 12/31/2025.
- Distribution
- Nationwide in the US
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 15 Oct 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.